• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, December 28, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Older patients with Crohn’s disease benefit from new medications

Bioengineer by Bioengineer
March 20, 2019
in Chemistry
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Combining medications that suppress the immune system has been successful in treating young patients with Crohn’s disease, but some physicians have been reluctant to use this strategy in older patients because of concerns about safety. Now an Alimentary Pharmacology & Therapeutics study indicates that older patients can be safely and effectively treated with such combined immunosuppression as well.

Among the 1,981 patients in the study, 311 were aged 60 years or older (173 randomised to early combined immunosuppression and 138 to conventional management). Over 24 months, 10 percent of older patients developed Crohn’s disease?related complications (6.4 percent of those in the combined immunosuppression group versus 14.5 percent of those in the conventional management group) and 14 patients died (3.5 percent versus 5.8 percent).

Among the patients who received combined immunosuppression in the study, older patients experienced remission of their disease to a similar extent as those aged under 60 years. There was also no increase in side effects from these medicines in older patients.

“It is important to treat aggressive Crohn’s disease appropriately regardless of age,” said lead author Dr. Siddharth Singh, of the University of California San Diego. “This may include early step-up combination therapy of tumour necrosis factor-alpha antagonists with thiopurines, which is effective and safe even in older patients, rather than treating these patients with chronic or repeated courses of corticosteroids.”

###

Media Contact
Penny Smith
[email protected]
http://dx.doi.org/10.1111/apt.15214

Tags: cancerMedicine/HealthPharmaceutical SciencePublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Cutting Electrolyte Reduction Boosts High-Energy Battery Performance

Cutting Electrolyte Reduction Boosts High-Energy Battery Performance

December 19, 2025
Microenvironment Shapes Gold-Catalysed CO2 Electroreduction

Microenvironment Shapes Gold-Catalysed CO2 Electroreduction

December 11, 2025

Photoswitchable Olefins Enable Controlled Polymerization

December 11, 2025

Cation Hydration Entropy Controls Chloride Ion Diffusion

December 10, 2025
Please login to join discussion

POPULAR NEWS

  • Robotic Waist Tether for Research Into Metabolic Cost of Walking

    NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    71 shares
    Share 28 Tweet 18
  • Nurses’ Views on Online Learning: Effects on Performance

    70 shares
    Share 28 Tweet 18
  • Exploring Audiology Accessibility in Johannesburg, South Africa

    51 shares
    Share 20 Tweet 13
  • Unraveling Levofloxacin’s Impact on Brain Function

    55 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Advancements in Computerized Liver Tumor Ablation Planning

Pilot Study: Haptic VR Simulation for Nursing Students

Unraveling Bisphenol A’s Stroke Toxicity Mechanisms

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.